发布求助
文献互助 智能选刊 最新文献

Clinical Lipidology最新文献

筛选
英文 中文
The association of dyslipidemia with erythrocyte aggregation 血脂异常与红细胞聚集的关系
Clinical Lipidology Pub Date : 2015-04-01 DOI: 10.2217/clp.15.3
P. Gyawali, R. Richards, P. Bwititi, E. Nwose
{"title":"The association of dyslipidemia with erythrocyte aggregation","authors":"P. Gyawali, R. Richards, P. Bwititi, E. Nwose","doi":"10.2217/clp.15.3","DOIUrl":"https://doi.org/10.2217/clp.15.3","url":null,"abstract":"Abstract Aim: The present study aims to associate erythrocyte aggregation with plasma lipid concentration. Materials & Methods: Ninety-nine participants were divided into two groups: normolipidemic and dyslipidemic. Lipid parameters were measured from serum and erythrocyte aggregation parameters: critical stress and critical time were measured from whole blood. Data were analyzed using IBS SPSS statistics software. Results: Erythrocyte aggregation was higher in the dyslipidemic group when compared with the normolipidemic group. Erythrocyte aggregation was associated with the abnormalities in lipid parameters, with the association of HDL-cholesterol and triglyceride being stronger than that of LDL-cholesterol and total cholesterol. Conclusion: The strong association of triglyceride and HDL-cholesterol with erythrocyte aggregation emphasizes the role of these lipids in the cardiovascular system.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"1 1","pages":"129 - 135"},"PeriodicalIF":0.0,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79885705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
The appropriate clinical use of niacin in the treatment of dyslipidemia 临床适当应用烟酸治疗血脂异常
Clinical Lipidology Pub Date : 2015-02-01 DOI: 10.2217/clp.14.60
M. Houston, Mimi Guarneri, J. Kahn
{"title":"The appropriate clinical use of niacin in the treatment of dyslipidemia","authors":"M. Houston, Mimi Guarneri, J. Kahn","doi":"10.2217/clp.14.60","DOIUrl":"https://doi.org/10.2217/clp.14.60","url":null,"abstract":"Abstract “The claim that HPS2 THRIVE proved that niacin induced more adverse effects than the statin arm of the study is not supported by the data.”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"129 1","pages":"17 - 22"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81336491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges to determining whether DHA can protect against age-related cognitive decline 确定DHA是否可以防止与年龄相关的认知能力下降的挑战
Clinical Lipidology Pub Date : 2015-02-01 DOI: 10.2217/clp.14.61
Marie Hennebelle, E. Harbeby, S. Tremblay, R. Chouinard‐Watkins, F. Pifferi, M. Plourde, P. Guesnet, S. Cunnane
{"title":"Challenges to determining whether DHA can protect against age-related cognitive decline","authors":"Marie Hennebelle, E. Harbeby, S. Tremblay, R. Chouinard‐Watkins, F. Pifferi, M. Plourde, P. Guesnet, S. Cunnane","doi":"10.2217/clp.14.61","DOIUrl":"https://doi.org/10.2217/clp.14.61","url":null,"abstract":"Abstract DHA, an omega-3 fatty acid, is an important constituent of brain membranes and has a key role in brain development and function. This review aims to highlight recent research on DHA’s role during age-related cognitive decline and Alzheimer’s disease. Animal and in vitro studies have provided some interesting mechanistic leads, especially on brain glucose metabolism, that may be involved in neuroprotection by DHA. However, results from human studies are more mitigated, perhaps due to changing DHA metabolism during aging. Recent innovative tools such as 13C-DHA for metabolic studies and 11C-DHA for PET provide interesting opportunities to study factors that affect DHA homeostasis during aging and to better understand whether and how to use DHA to delay or treat Alzheimer’s disease.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"31 1","pages":"102 - 91"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87034600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Understanding adipocyte types and adipose tissue dynamics for obesity management 了解肥胖管理中的脂肪细胞类型和脂肪组织动力学
Clinical Lipidology Pub Date : 2015-02-01 DOI: 10.2217/clp.14.58
P. Zahradka, Carla G. Taylor
{"title":"Understanding adipocyte types and adipose tissue dynamics for obesity management","authors":"P. Zahradka, Carla G. Taylor","doi":"10.2217/clp.14.58","DOIUrl":"https://doi.org/10.2217/clp.14.58","url":null,"abstract":"Abstract “ The key to this strategy will be to identify ways of inducing white adipose tissue browning and applying this knowledge clinically as a means of treating and preventing obesity.”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"18 1","pages":"23 - 26"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75486659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Public health implications of milk fats: the current evidence base and future directions 乳脂对公共健康的影响:目前的证据基础和未来的方向
Clinical Lipidology Pub Date : 2015-02-01 DOI: 10.2217/clp.14.66
O. Markey, D. Hobbs, D. Givens
{"title":"Public health implications of milk fats: the current evidence base and future directions","authors":"O. Markey, D. Hobbs, D. Givens","doi":"10.2217/clp.14.66","DOIUrl":"https://doi.org/10.2217/clp.14.66","url":null,"abstract":"Abstract “overall, the evidence from prospective cohort studies shows that milk/dairy consumption does not increase cardiovascular disease risk.”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"20 1","pages":"5 - 8"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74116744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Krill oil: evidence of a new source of polyunsaturated fatty acids with high bioavailability 磷虾油:具有高生物利用度的多不饱和脂肪酸新来源的证据
Clinical Lipidology Pub Date : 2015-02-01 DOI: 10.2217/clp.14.67
A. Cicero, A. Colletti
{"title":"Krill oil: evidence of a new source of polyunsaturated fatty acids with high bioavailability","authors":"A. Cicero, A. Colletti","doi":"10.2217/clp.14.67","DOIUrl":"https://doi.org/10.2217/clp.14.67","url":null,"abstract":"Abstract “preliminary clinical trials suggest that Krill oil is an alternative source of polyunsaturated fatty acids with peculiar effects in humans.”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"73 1","pages":"1 - 4"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74394160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
The National Lipid Association’s new recommendations for patient-centered management of cholesterol 国家脂质协会关于以病人为中心的胆固醇管理的新建议
Clinical Lipidology Pub Date : 2015-02-01 DOI: 10.2217/CLP.14.68
James A. Underberg
{"title":"The National Lipid Association’s new recommendations for patient-centered management of cholesterol","authors":"James A. Underberg","doi":"10.2217/CLP.14.68","DOIUrl":"https://doi.org/10.2217/CLP.14.68","url":null,"abstract":"James Underberg, MD, is a clinical assistant professor of medicine and clinical lipidologist at New York University Medical School and the NYU Center for Prevention of Cardiovascular Disease. He is the Director of the Lipid Clinic at Bellevue Hospital in New York City. He is also a member of the board of directors of the National Lipid Association, and serves on the scientific advisory board of the FH Foundation. He serves on the editorial board of the Journal of Clinical Lipidology. Dr. Underberg's clinical interests focus on the clinical management of patients with lipids and lipoprotein disorders, hypertension management and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of clinical lipidology.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"94 1","pages":"13 - 15"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73287440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Twenty-five years of statins: where do we go from here? 25年的他汀类药物:我们该何去何从?
Clinical Lipidology Pub Date : 2015-02-01 DOI: 10.2217/clp.14.62
A. Gotto, Jennifer E. Moon
{"title":"Twenty-five years of statins: where do we go from here?","authors":"A. Gotto, Jennifer E. Moon","doi":"10.2217/clp.14.62","DOIUrl":"https://doi.org/10.2217/clp.14.62","url":null,"abstract":"Abstract More than 25 years of clinical trial data have established statins as first-line therapy for the prevention and treatment of atherosclerotic cardiovascular disease. With regard to low-density lipoprotein cholesterol, a wealth of evidence indicates that ‘lower is better,’ although recent guidelines from the American College of Cardiology and the American Heart Association take a different approach. A variety of approved and experimental lipid-lowering agents may be used as supplements or alternatives to statin therapy in patient subgroups, including those with familial hypercholesterolemia, mixed dyslipidemia or statin intolerance. Strategies to achieve further reductions in low-density lipoprotein cholesterol, target high-density lipoprotein cholesterol and triglycerides or reduce inflammation may help address residual cardiovascular risk, although early lifestyle interventions are crucial to prevention strategies.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"23 1","pages":"33 - 45"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78531595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Why are there inconsistencies in the outcomes of some omega-3 fatty acid trials for the management of cardiovascular disease? 为什么一些omega-3脂肪酸治疗心血管疾病的试验结果不一致?
Clinical Lipidology Pub Date : 2015-02-01 DOI: 10.2217/clp.15.1
N. Shaikh, P. Tappia
{"title":"Why are there inconsistencies in the outcomes of some omega-3 fatty acid trials for the management of cardiovascular disease?","authors":"N. Shaikh, P. Tappia","doi":"10.2217/clp.15.1","DOIUrl":"https://doi.org/10.2217/clp.15.1","url":null,"abstract":"Abstract “With mixed results in recent clinical trials and meta-analyses some doubt has been raised on the efficacy of omega-3 polyunsaturated fatty acidsfor management of cardiovascular disease.”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"11 1","pages":"27 - 32"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89178045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
High-density lipoproteins at the interface between central nervous system and plasma lipoprotein metabolism 高密度脂蛋白在中枢神经系统和血浆脂蛋白代谢之间的界面
Clinical Lipidology Pub Date : 2015-02-01 DOI: 10.2217/clp.14.64
J. Robert, Wai Hang Cheng, Arooj Hayat, Taylor Ward-Able, C. Wellington
{"title":"High-density lipoproteins at the interface between central nervous system and plasma lipoprotein metabolism","authors":"J. Robert, Wai Hang Cheng, Arooj Hayat, Taylor Ward-Able, C. Wellington","doi":"10.2217/clp.14.64","DOIUrl":"https://doi.org/10.2217/clp.14.64","url":null,"abstract":"Abstract The brain is the most lipid-rich organ in the body and contains 25% of the body’s total cholesterol content. ApoE is the major apolipoprotein expressed in the brain and genetic variations in apoE underlie much of the genetically determined risk of late-onset Alzheimer’s disease. Regulation of lipid homeostasis in the CNS is therefore of great interest for healthy brain aging. The brain’s lipid transport system is built around lipoprotein particles that are similar in size and presumed function to circulating HDL. It is increasingly appreciated that many comorbidities that increase Alzheimer’s disease risk include aspects of aberrant HDL-metabolism, yet how circulating HDL may impact brain health is not fully understood. As comprehending the similarities and differences between CNS and peripheral lipid metabolism may reveal important relationships between cardiovascular and neurological diseases, here we review the fundamental properties of HDL metabolism in both peripheral and CNS compartments.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"5 1","pages":"69 - 81"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88214430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信